A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...
The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback